Introduction {#sec1_1}
============

Fibrosis is the final result of chronic liver diseases regardless of etiology. The extent of fibrosis is essential not only for the prognosis but also for the treatment of chronic liver diseases. Liver biopsy remains the gold standard for the assessment of liver fibrosis. However, it is an invasive procedure and not without risks. Moreover, liver histological lesions change with time, stressing the need for periodic assessment of liver histology by repeated liver biopsies, which increase the cost, give rise to questions concerning life quality and ethical issues, and are often refused by the patients. All these aspects together with the possibility of complications \[[@B1]\], sampling errors \[[@B2]\], and inter- and intra-pathologists variability \[[@B3]\] have stimulated the research for non-invasive markers of fibrosis.

Transient elastography is a new, non-invasive method that measures liver tissue stiffness. Transient elastography by Fibroscan samples a volume of approximately 4 cm^3^, which is more representative of liver tissue than a liver biopsy specimen. Measurements can usually be performed quickly and are highly reproducible, while they may be inaccurate or impossible in patients with obesity, ascites or narrow intercostal spaces \[[@B4]\]. Transient elastography has also been demonstrated to be a reliable tool for assessing fibrosis and cirrhosis mainly in patients with chronic hepatitis C (CHC) \[[@B5], [@B6]\]. Although there are some studies evaluating the accuracy of elastography in patients with chronic liver diseases of other etiologies \[[@B7], [@B8]\], more data are required in these settings, particularly in patients with chronic hepatitis B (CHB), who represent a large group of patients with chronic liver disease in many areas worldwide.

The purpose of this study was to assess the accuracy of liver stiffness measurement by elastography for the diagnosis of severe fibrosis and cirrhosis as estimated by liver biopsy in patients with CHB or CHC.

Materials and Methods {#sec1_2}
=====================

Patient Population {#sec2_1}
------------------

We included 75 consecutive patients with chronic viral hepatitis (CHB: n = 45, CHC: n = 32) who underwent transient elastography and liver biopsy at the same time from July 2007 until October 2008. Patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection, detectable antibodies against hepatitis delta virus (anti-HDV) or against human immunodeficiency virus (anti-HIV), other causes of liver injury (alcohol abuse, use of known hepatotoxic drugs, autoimmune hepatitis, metabolic or cholestatic liver diseases) and malignancy were excluded. No patient had decompensated liver disease (history or evidence of ascites, variceal bleeding, hepatic encephalopathy or jaundice). The diagnosis of CHB was made in cases who were HBsAg positive for at least 6 months, who had increased alanine aminotransferase (ALT) activity \[ALT \> upper limit of normal (ULN)\] on at least two separate monthly determinations within the last 6 months and serum HBV DNA \>2,000 IU/ml. The diagnosis of CHC was made in cases with detectable antibodies against HCV (anti-HCV) and HCV RNA in serum.

Methods {#sec2_2}
-------

Data about weight and height on the liver biopsy day as well as about average alcohol consumption during the 5 years preceding the liver biopsy, smoking, concurrent diseases and treatment were recorded from all patients. Alcohol abuse was defined as a mean daily consumption of \>60 g of alcohol for male and \>40 g for female patients over the last 6 months. Full blood count including platelet count (PLT), prothrombin time and liver function tests \[ALT, aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl-transpeptidase (GGT)\] were evaluated by commercially available assays in all patients on the liver biopsy day. Commercially available enzyme immunoassays were used for the detection of HBV markers (HBsAg, HBeAg, anti-HBe), anti-HCV and anti-HIV and commercially available polymerase chain reaction assays for the detection of serum HBV DNA and HCV RNA.

Transient Elastography {#sec2_3}
----------------------

All transient elastographies were performed by one of two operators (M.-V.P., H.K.) and the result was considered reliable when the success rate (valid to total measurements) was \>60% and the interquartile range (IQR) \<30% of the final liver stiffness, as previously suggested by others \[[@B9]\].

Liver Histology {#sec2_4}
---------------

All 75 patients had an adequate biopsy specimen with a length of ≥1.5 cm. All liver biopsies were evaluated by one blinded liver histopathologist (G.K.) and the histological changes of chronic hepatitis were classified according to the classification proposed by Ishak et al. \[[@B10]\]. The chronic hepatitis grading score (0--18), which represents the necroinflammatory activity, was the sum of piecemeal necrosis score (0--4), confluent necrosis score (0--6), focal lytic necrosis, apoptosis and focal inflammation score (0--4) and portal inflammation score (0--4). The chronic hepatitis staging score (0--6), which is referred to as the fibrosis score, was based on the degree and extent of fibrosis, architectural alterations and development of cirrhosis. Fibrosis score 0--1 was considered as absence of fibrosis or mild fibrosis. Advanced staging or significant fibrosis was considered as a staging/fibrosis score of 4--6 and cirrhosis as a staging/fibrosis score of 5--6.

Statistical Analysis {#sec2_5}
--------------------

All data were analyzed using the statistical package SPSS 15.0. Quantitative variables with normal distribution were expressed as mean values ± standard deviation (SD) and those with abnormal distribution as median values (range). Statistical analysis was performed using t test or Mann-Whitney test for comparisons of quantitative variables between groups, Spearman\'s coefficient for correlations of quantitative variables and corrected χ^2^ method or two-tailed Fisher\'s exact test for qualitative data, when appropriate. Transient elastography was evaluated using the liver stiffness both as a quantitative and qualitative variable after having classified patients into groups according to their liver stiffness (≤12.5 or \>12.5 kPa) for prediction of cirrhosis. The accuracy of transient elastography for predicting no/mild fibrosis, significant fibrosis or cirrhosis was assessed by the area under the receiver operating characteristic (ROC) curve. A two-tailed p value of \<0.05 was considered to be statistically significant.

Results {#sec1_3}
=======

The baseline characteristics of all patients are presented in table [1](#T1){ref-type="table"}. Patients with CHB compared to those with CHC were more frequently males and had a higher mean value of liver stiffness. According to the stage of fibrosis, most (29/75 or 39%) of our patients had no or mild fibrosis, while significant fibrosis or cirrhosis was observed in 25 (33%) of the 75 patients. Patients with significant fibrosis or cirrhosis compared to those with moderate, compared to those with no or mild fibrosis were older (mean ± SD age: 56 ± 11 vs. 50 ± 14 vs. 43 ± 13 years, p = 0.003), had a relatively higher BMI (26 ± 5 vs. 26 ± 2 vs. 24 ± 3 kg/m^2^, p = 0.059), worse necroinflammatory activity (7 ± 3 vs. 5 ± 2 vs. 4 ± 2, p \< 0.001), and greater liver stiffness (16.8 ± 9.5 vs. 6.6 ± 2.8 vs. 5.8 ± 2.2 kPa, p = \<0.001).

Liver stiffness was found to be significantly associated with the fibrosis stage (p \< 0.001), but there was wide overlap in the values of liver stiffness among the different stages of fibrosis (fig. [1](#F1){ref-type="fig"}). In particular, the mean (SD) liver stiffness (kPa) was 5.8 (2.2), 6.6 (2.8), 11.3 (5.0) and 19.4 (5.0) in patients with fibrosis stage 0--1, 2--3, 4 and 5--6, respectively (p \< 0.001).

Liver stiffness was found to have moderate accuracy for predicting absence of fibrosis (stage 0--1) (c-statistic: 0.784) without significant difference between patients with CHB or CHC. The accuracy of prediction for moderate fibrosis did not substantially change (c-statistic: 0.747) when only patients with elastography with IQR \<30% of liver stiffness were included.

On the contrary, liver stiffness was found to have excellent accuracy for predicting severe fibrosis (stage 4--6) (c-statistic: 0.926) in all patients as well as in patients with CHB (c-statistic: 0.902) or CHC (c-statistic: 0.952) (fig. [2](#F2){ref-type="fig"}). The accuracy of prediction for severe fibrosis did not change significantly (c-statistic: 0.940) when only patients with elastography with IQR \<30% of liver stiffness were included.

The accuracy of liver stiffness for predicting cirrhosis (stage 5--6) was also excellent (c-statistic: 0.948) without significant difference between patients with CHB or CHC (c-statistic: 0.930 vs. 0.960) (fig. [3](#F3){ref-type="fig"}). Again, there was no change in the accuracy of prediction for cirrhosis (c-statistic: 0.960) when only patients with elastography with IQR \<30% of liver stiffness were included.

When a widely proposed cutoff value of 12.5 kPa for predicting cirrhosis was used, 10 (13%) of the 75 patients were found to be misclassified (5 with cirrhosis overestimation, 5 with cirrhosis underestimation). Misclassified patients were older, more obese, under antiviral therapy and had a wider range of liver stiffness measurements (IQR \>30%) (table [2](#T2){ref-type="table"}). In our population, transient elastography underestimated 29.4% of cirrhotic patients. On the other hand, 8.6% of the patients were classified as cirrhotic by transient elastography, while no cirrhosis was observed according to the biopsy specimen.

Discussion {#sec1_4}
==========

Chronic viral hepatitis is an important issue of public health worldwide, which is associated with increased morbidity and mortality. The main therapeutic goal for patients with chronic viral hepatitis is the prevention of cirrhosis-associated complications and hepatocellular carcinoma. Assessment of the degree of hepatic fibrosis is important not only to determine the prognosis of chronic liver disease but also to select patients for treatment and to monitor the success of treatment. Despite the significant progress in diagnosis and therapeutic intervention over the last decade, there is still a substantial proportion of patients that cannot be treated effectively \[[@B11]\]. Additionally, because of the high cost and the potential side effects of the anti-HCV agents and the unknown, perhaps indefinite, treatment duration of oral anti-HBV agents, therapy may often be recommended in patients with significant histological lesions or a high risk of worsening liver histology. Thus, staging is important for the estimation of prognosis and decision for therapeutic intervention.

Liver biopsy is currently the gold standard for the assessment of liver fibrosis. However, it is an invasive procedure associated with patient discomfort and occasionally with serious complications. In addition, the accuracy of the procedure is limited due to intra- and inter-observer variability and sampling errors \[[@B1], [@B2], [@B3]\]. Even when biopsy is performed and interpreted by an expert, it has an error rate in disease staging of up to 20%. Moreover, liver histological lesions change with time, stressing the need for periodic assessment of liver histology by repeated liver biopsies, which, however, increase the cost, give rise to questions concerning life quality and ethical issues and, most importantly, are often refused by the patients.

The limitations of percutaneous liver biopsy and particularly the difficulty in performing repeated procedures have increased the need for non-invasive means to assess liver histological lesions. Different approaches to estimate liver fibrosis non-invasively have been proposed, including indirect fibrosis tests based on routine liver function parameters, direct fibrosis tests based on extracellular matrix proteins and physical methods that estimate fibrosis by measuring liver stiffness.

Transient elastography by Fibroscan is a relatively new, easy to perform, and promising technique that estimates the degree of hepatic fibrosis by measuring liver stiffness \[[@B4]\]. Fibroscan samples a volume of approximately 4 cm^3^, which is more representative of the entire liver than a needle biopsy specimen. Measurements are quickly performed and are highly reproducible. Liver stiffness measurements range from 2.5 to 75 kPa.

In this study, liver stiffness values were found to be significantly associated with the extent of fibrosis, but there were significant overlaps in these values among patients with different histological stages (fig. [1](#F1){ref-type="fig"}). This finding is in accordance with the results of other studies \[[@B9]\], which also showed wide overlaps of liver stiffness values between adjacent stages of hepatic fibrosis, particularly for mild stages of fibrosis.

The area under ROC curve for the prediction of no or mild fibrosis was 0.784 and there was no liver stiffness value offering both sensitivity and specificity over 70%. The accuracy of liver stiffness values for the prediction of severe fibrosis and cirrhosis was excellent with areas under ROC curves being \>0.90 when CHB and CHC patients were analyzed together or separately. These findings are also in agreement with previous reports further supporting the excellent overall predictability of Fibroscan of the presence of advanced fibrosis or cirrhosis in patients with chronic viral hepatitis \[[@B9], [@B12]\]. Despite the excellent results from the ROC curves analyses, however, it was impossible to identify very strong cutoff stiffness values in our patients. In particular, no stiffness value offered both sensitivity and specificity over 80% for the prediction of severe fibrosis or cirrhosis.

The stiffness cutoff values for cirrhosis have been reported to range from 10.3 kPa in patients with CHB \[[@B13]\] to 17.3 kPa in patients with cholestatic diseases \[[@B7]\], but the optimal cutoff value remains to be determined. Using the stiffness cutoff value of 12.5 kPa proposed by Castera et al. \[[@B14]\] for the prediction of cirrhosis in patients with CHC, we examined the cases with discordance between transient elastography and liver biopsy findings. We found that 13% of our 75 patients were misclassified (7% in the study of Castera et al. \[[@B14]\]). In particular, cirrhosis was overestimated by Fibroscan in 5 and underestimated in another 5 cases. The 10 patients misclassified compared to patients correctly classified by elastography were older, under antiviral treatment and had more frequently an unreliable test (IQR \>30% of the median value \[[@B9]\]). The latter characteristic may be, at least partly, responsible for the relatively rarer misclassification rate in the study of Castera et al., in which only patients with IQR \<30% of the median stiffness values were included \[[@B14]\]. It should be noted, however, that many patients with elastographies considered to be unreliable (IQR \>30% of liver stiffness) were classified correctly according to their liver stiffness measurements, and therefore the exclusion of these cases did not affect the overall accuracy of prediction of elastography in our study.

In conclusion, our data further support that liver stiffness measurements by transient elastography are strongly associated with the extent of fibrosis \[[@B9], [@B12]\]. Fibroscan\'s diagnostic accuracy for the presence of advanced fibrosis or cirrhosis in patients with chronic viral hepatitis was found to be excellent (AUROC \>0.90). We should keep in mind that, as recently suggested by Mehta et al. \[[@B15]\], even in the best scenario where liver biopsy accuracy is highest, the calculated AUROC would be 0.90. However, transient elastography cannot replace liver biopsy yet, particularly in the initial evaluation of patients with chronic viral hepatitis, mainly because it may misclassify approximately 10% of cases for the presence of cirrhosis \[[@B14]\]. Moreover, liver biopsy offers additional information on all types of histological lesions and not only on liver fibrosis. The optimal cutoff of liver stiffness values for the prediction of cirrhosis and whether this may be specifically defined for each type of chronic liver disease remains to be determined \[[@B16]\]. In our study, there was no difference in the prognostic accuracy of elastography for the extent of fibrosis between patients with CHB and CHC. Since transient elastography is easy to perform and has excellent patient acceptance, it seems to be very useful for monitoring changes of fibrosis in the individual patient. It should be noted, however, that the potential effect of treatment on the accuracy of elastography has not been adequately studied to date and, therefore, more data in patients under therapy should be obtained before the wide establishment of such a use of elastography in routine clinical practice.
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![Liver stiffness values by elastography for each stage of fibrosis. Box and whisker plots express median values and interquartile and overall ranges. Liver stiffness values are significantly higher in more severe stages of fibrosis (p \< 0.001), but there are significant overlaps among the different fibrosis stages.](crg0005-0063-f01){#F1}

![ROC curve for the prediction of severe fibrosis (stage 4--6) by liver elastography. Liver stiffness values have excellent overall accuracy for predicting severe fibrosis (c-statistic: 0.926) in all patients with CHB or CHC (**A**) as well as in patients with CHB only (c-statistic: 0.902) (**B**) or patients with CHC only (c-statistic: 0.952) (**C**).](crg0005-0063-f02){#F2}

![ROC curve for the prediction of cirrhosis (stage 5--6) by liver elastography. The accuracy of liver stiffness for predicting cirrhosis is excellent in all patients with CHB or CHC (c-statistic: 0.948) (**A**) as well as in patients with CHB only (c-statistic: 0.930) (**B**) or patients with CHC only (c-statistic: 0.960) (**C**).](crg0005-0063-f03){#F3}

###### 

Baseline characteristics of 75 patients with CHB or CHC

                          CHB (n = 43)   CHC (n = 32)   Total (n = 75)   p
  ----------------------- -------------- -------------- ---------------- -------
  Sex, males (%)          33 (77)        16 (50)        49 (65)          0.017
  Age, years              48 ± 14        51 ± 13        49 ± 14          0.419
  Height, m               1.7 ± 0.1      1.7 ± 0.1      1.7 ± 0.1        0.836
  Weight, kg              72.8 ± 11.7    72.6 ± 13.6    72.7 ± 12.4      0.930
  BMI, kg/m^2^            25.2 ± 2.7     25.4 ± 4.3     25.3 ± 3.5       0.851
  Other diseases, n (%)   8 (19)         8 (25)         16 (21)          0.357
  Alcohol, n (%)          6 (14)         4 (12)         10 (13)          0.259
  Smoking, n (%)          16 (37)        16 (50)        32 (43)          0.135
  Under therapy, n (%)    19 (44)        14 (44)        33 (44)          0.882
  Necroinflammation       5 ± 2          5 ± 2          5 ± 2            0.443
  Fibrosis                3 ± 2          3 ± 2          3 ± 2            0.369
  Liver stiffness, kPa    7.7 ± 5.0      12.3 ± 9.7     9.7 ± 7.7        0.009

BMI = Body mass index.

###### 

Characteristics of correctly and falsely classified patients in relation to the presence of cirrhosis and the stiffness cut off of 12.5 kPa at transient elastography

                          Correct classification (n = 65)   Wrong classification (n = 10)   p
  ----------------------- --------------------------------- ------------------------------- -------
  Sex, males (%)          42 (65)                           7 (70)                          0.739
  Age, years              47 ± 13                           63 ± 11                         0.001
  BMI, kg/m^2^            25.3 ± 3.5                        25.1 ± 3.6                      0.844
  Type of CH, n (%)                                                                         
  CHB                     37 (57)                           6 (60)                          
   CHC                    28 (43)                           4 (40)                          0.855
  Under therapy, n (%)    24 (37)                           9 (90)                          0.001
  Other diseases, n (%)   12 (18)                           4 (40)                          0.140
  Drugs, n (%)            20 (31)                           6 (60)                          0.075
  Alcohol, n (%)          8 (12)                            2 (20)                          0.713
  Smoking, n (%)          30 (46)                           2 (20)                          0.027
  IQR/stiffness (\>30%)   56 (86)                           5 (50)                          0.006

BMI = Body mass index; IQR = interquartile range.
